Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-20, Stock:NVS, The news for the past five days is as follows:
2019-08-13: NEWS1: Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales.NEWS2: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS3: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS4: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS5: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS6: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS7: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS8: Pre-Market Most Active for Aug 13, 2019 :  JD, UBS, DCPH, TVIX, NVS, GE, AMD, SQQQ, QQQ, TME, BABA, BE.NEWS9: Pre-Market Most Active for Aug 13, 2019 :  JD, UBS, DCPH, TVIX, NVS, GE, AMD, SQQQ, QQQ, TME, BABA, BE.NEWS10: 5 Biggest New Drugs Approved in 2019 So Far.NEWS11: 5 Biggest New Drugs Approved in 2019 So Far.NEWS12: 5 Biggest New Drugs Approved in 2019 So Far.
2019-08-14: NEWS1: Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data.NEWS2: Wednesday’s Vital Data: Amgen, American Airlines and Apple.NEWS3: Wednesday’s Vital Data: Amgen, American Airlines and Apple.NEWS4: Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%.NEWS5: Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%.NEWS6: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS7: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS8: UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated.NEWS9: Everyone’s Mad At Novartis. But the Stock Is Doing Just Fine.NEWS10: Novartis replaces top scientists at Avexis after drug data manipulated.NEWS11: Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%.NEWS12: Wednesday’s Vital Data: Amgen, American Airlines and Apple.NEWS13: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS14: Novartis names Bulto as new head of U.S. drugs business.NEWS15: Novartis ousted scientists before reporting drug data manipulation.
2019-08-15: NEWS1: Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future.NEWS2: Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat.NEWS3: Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat.NEWS4: Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat.NEWS5: Novartis replaces top scientists at Avexis after drug data manipulated.NEWS6: PRESS DIGEST- Financial Times - Aug 15.
2019-08-16: NEWS1: A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis.NEWS2: A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis.NEWS3: AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL.NEWS4: AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL.NEWS5: A Breach of Trust? Here&apos;s Why the FDA&apos;s Taking Aim at Novartis&apos; AveXis.NEWS6: AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL.NEWS7: Gene therapies to test FDA's approach to regulating drugs after launch, experts say.
2019-08-19: NEWS1: INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS2: 5 Companies Still Run by Families.NEWS3: 5 Companies Still Run by Families.NEWS4: EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS.NEWS5: 5 Companies Still Run by Families.NEWS6: AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA.NEWS7: AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA.NEWS8: AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA.NEWS9: 5 Biggest New Drug Approvals Potentially on the Way in 2019.NEWS10: 5 Biggest New Drug Approvals Potentially on the Way in 2019.NEWS11: 5 Biggest New Drug Approvals Potentially on the Way in 2019.NEWS12: Novartis to answer U.S. Senate demand for data manipulation details.NEWS13: Novartis executive sold almost $1m shares ahead of FDA probe.NEWS14: Novartis faces further fallout over Zolgensma.

Answer: Decrease